```html

Nicotinitis (E‑Cigarette or Vaping‑Associated Lung Injury)

Overview

Nicotinitis, commonly known as E‑Cigarette or Vaping‑Associated Lung Injury (EVALI), is an acute inflammatory lung condition linked to the use of e‑cigarettes or vaping devices. First recognized in the United States in 2019, the condition can range from mild respiratory discomfort to life‑threatening respiratory failure.

Who is affected? Although anyone who inhales aerosolized vaping liquids is at risk, the majority of reported cases have occurred in adolescents and young adults (ages 13‑35). <sup>[1] CDC, 2023</sup>

Prevalence – From August 2019 to February 2020, the U.S. Centers for Disease Control and Prevention (CDC) recorded 2,805 confirmed or probable EVALI cases, including 68 deaths.<sup>[2]</sup> Since then, case numbers have sharply declined after public‑health warnings and product recalls, but sporadic cases continue worldwide, especially in regions with less regulation of vaping products.

Symptoms

The presentation is often non‑specific and can mimic viral pneumonia, asthma, or bronchitis. Symptoms usually develop within days to weeks after exposure.

• Respiratory:
  • Dry cough
  • Shortness of breath or difficulty breathing (dyspnea)
  • Chest pain or tightness
  • Wheezing
• Gastrointestinal:
  • Nausea or vomiting
  • Abdominal pain
  • Diarrhea
• Constitutional:
  • Fever (often > 38 °C/100.4 °F)
  • Chills
  • Fatigue or malaise
  • Weight loss (in severe or prolonged cases)
• Neurologic/Other:
  • Headache
  • Confusion or altered mental status (rare but reported)
  • Skin rash (occasionally)

Symptoms can progress rapidly; shortness of breath may worsen to the point of requiring supplemental oxygen or mechanical ventilation.

Causes and Risk Factors

Primary Causative Agents

Most EVALI cases have been linked to inhalation of aerosolized liquids that contain vitamin E acetate, a thickening agent used in some THC‑containing vape cartridges. However, other chemicals—such as medium‑chain triglycerides, propylene glycol, glycerol, flavoring agents (e.g., diacetyl), and nicotine salts—have also been implicated.

Risk Factors

• Age: Adolescents and young adults are the most affected group.
• Product Type: Use of THC‑containing or black‑market cartridges increases risk.
• Frequency & Duration: Daily or heavy use (multiple “puffs” per session) elevates exposure.
• Device Modification: “DIY” mixing of liquids or use of unregulated devices.
• Underlying Lung Disease: Asthma, COPD, or cystic fibrosis may worsen outcomes.
• Smoking History: Prior combustible‑cigarette use is a common background but not a direct cause.

Diagnosis

Because EVALI mimics many other pulmonary illnesses, diagnosis is one of exclusion and requires a systematic approach.

Clinical Evaluation

• Detailed history of vaping (substances, brands, frequency, and timeline of symptom onset).
• Physical examination focusing on respiratory findings (crackles, wheezes, oxygen saturation).

Laboratory and Imaging Studies

• Chest X‑ray: Often shows bilateral infiltrates, which may be diffuse or focal.
• High‑Resolution CT (HRCT) scan: More sensitive; typical patterns include:
  • Ground‑glass opacities (most common)
  • Consolidation
  • Crazy‑paving
  • Subpleural sparing
• Laboratory tests: CBC (possible leukocytosis), inflammatory markers (CRP, ESR), and basic metabolic panel.
• Microbiologic work‑up: Sputum culture, viral PCR panel, and testing for atypical bacteria (Mycoplasma, Legionella) to rule out infection.
• Bronchoscopy with bronchoalveolar lavage (BAL): Considered when diagnosis is uncertain; BAL fluid may contain lipid‑laden macrophages, suggestive but not definitive for EVALI.

Diagnostic Criteria (CDC)

1. Use of e‑cigarette or vaping product within 90 days before symptom onset.
2. Pulmonary infiltrates on imaging.
3. Absence of alternative plausible diagnoses (e.g., infection, cardiac disease).
4. Presence of at least one respiratory, gastrointestinal, or constitutional symptom.

Treatment Options

Acute Management

• Immediate cessation of vaping. This is the most critical step.
• Supportive care:
  • Supplemental oxygen for hypoxia.
  • Mechanical ventilation in severe respiratory failure.
• Corticosteroids: Systemic steroids (e.g., prednisone 40‑60 mg daily) have been shown to accelerate clinical improvement. Typical tapering schedules last 2‑4 weeks, but exact dosing should be individualized.<sup>[3] WHO Clinical Guidance, 2022</sup>
• Antibiotics: Empiric broad‑spectrum antibiotics are often started initially until infection is excluded.

Follow‑up Care

• Repeat imaging (CXR or CT) 1‑2 weeks after discharge to confirm resolution.
• Pulmonary function testing (PFT) at 1‑3 months to assess for lingering restrictive or obstructive changes.
• Referral to a pulmonologist for persistent symptoms.

Lifestyle & Rehabilitation

• Smoking cessation programs (nicotine replacement therapy, counseling).
• Breathing‑exercise programs (e.g., diaphragmatic breathing, incentive spirometry).
• Vaccinations: Influenza annually, COVID‑19 booster, and pneumococcal vaccine if indicated.

Living with Nicotinitis (E‑Cigarette or Vaping‑Associated Lung Injury)

Daily Management Tips

• Track respiratory symptoms: Keep a diary of cough, breathlessness, and temperature.
• Stay hydrated: Adequate fluids help clear mucus and support lung healing.
• Optimize indoor air quality: Use HEPA filters, avoid second‑hand smoke, dust, and strong fragrances.
• Gradual physical activity: Begin with short walks, progressing as tolerance improves; avoid high‑intensity exercise until clearance from a physician.
• Medication adherence: Complete steroid taper as prescribed; never stop abruptly without medical advice.
• Psychological support: Many patients feel anxiety about lung health; counseling or support groups can aid coping.

Monitoring Tools

Pulse oximeters are inexpensive and can help you monitor oxygen saturation at home. Seek urgent care if SpO₂ falls below 92 % on room air.

Prevention

• Avoid all vaping products, especially those containing THC or purchased from informal sources.
• Read ingredient lists. Products that list vitamin E acetate, MCT oil, or “thickening agents” should be avoided.
• Regulation awareness. Use only products approved by national health agencies (e.g., FDA‑authorized nicotine‑containing e‑cigs in the U.S.).
• Education. Parents, teachers, and healthcare providers should discuss the risks of vaping with youths.
• Smoking cessation support. For adults who smoke, evidence‑based cessation programs are safer than switching to vaping.

Complications

If untreated or if the injury is severe, complications can be life‑threatening.

• Acute respiratory distress syndrome (ARDS): Diffuse alveolar damage requiring mechanical ventilation.
• Secondary bacterial or fungal pneumonia: Damaged lung tissue is more susceptible to infection.
• Bronchiectasis: Permanent airway dilation after chronic inflammation.
• Pulmonary fibrosis: Scarring that can cause long‑term restrictive lung disease.
• Cardiovascular strain: Persistent hypoxia can precipitate arrhythmias or right‑heart failure.
• Psychosocial impact: Anxiety, depression, and reduced quality of life due to chronic respiratory limitation.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. Outbreak of Lung Injury Associated with the Use of E‑Cigarette, or Vaping, Products. 2023. cdc.gov
2. CDC. EVALI Cases and Deaths by State. Updated February 2024. cdc.gov
3. World Health Organization. Clinical Management of E‑Cigarette or Vaping Associated Lung Injury (EVALI). 2022. who.int
4. Mayo Clinic. E‑Cigarette or Vaping‑Associated Lung Injury (EVALI). 2023. mayoclinic.org
5. Cleveland Clinic. Vaping‑Related Lung Injury: What You Need to Know. 2022. clevelandclinic.org

```